Multiplex Assay Kit for Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay)
CCL3; MIP1-A; SCYA3; Chemokine C-C-Motif Ligand 3; Small Inducible Cytokine A3; Homologous To Mouse Mip-1a; Tonsillar Lymphocyte LD78 Alpha Protein
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 348.00 US$ 362.00 US$ 382.00 US$ 409.00 US$ 436.00 US$ 476.00 US$ 536.00 US$ 670.00
- Quantity
Overview
Properties
- Product No.LMA092Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryCytokineInfection immunity
Sign into your account
Share a new citation as an author
Upload your experimental result
Review

Contact us
Please fill in the blank.
Recovery
Matrices listed below were spiked with certain level of recombinant Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 95-103 | 99 |
EDTA plasma(n=5) | 97-104 | 101 |
heparin plasma(n=5) | 80-103 | 80 |
sodium citrate plasma(n=5) | 83-96 | 88 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 96-103% | 98-105% | 99-105% | 85-93% |
EDTA plasma(n=5) | 95-104% | 93-104% | 83-94% | 99-105% |
heparin plasma(n=5) | 79-89% | 79-93% | 99-105% | 82-101% |
sodium citrate plasma(n=5) | 95-103% | 82-90% | 79-103% | 94-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:MIP1a) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Age influence on hypersensitivity pneumonitis induced in mice by exposure to Pantoea agglomeransPubmed: 24044680
- The Transcriptional Foundations of Sp110-mediated Macrophage (RAW264. 7) Resistance to Mycobacterium tuberculosis H37RaPubmed:26912204
- CIRCULATING MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (MIP1-Α) AS A POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PATIENTS WITH …57e97ac908aeb34bc08fd41a.pdf
- Role of Gut-Derived Endotoxin on Type I Collagen Production in the Rat Pancreas after Chronic Alcohol Exposure pubmed:29121396
- Changes in the concentrations of inflammatory and oxidative status biomediators (MIP-1 α, PMN elastase, MDA, and IL-12) in depressed patients with and without posttraumatic stress disorder10.1016/j.pharep.2017.08.008
- Molybdenum disulfide/graphene oxide nanocomposites show favorable lung targeting and enhanced drug loading/tumor-killing efficacy with improved …Articles:am2017225
- Therapeutic Potential of Pien Tze Huang on Experimental Autoimmune Encephalomyelitis RatPubmed:29682587
- Cathelicidin LL-37 affects surface and intracellular Toll-like receptor expression in tissue mast cellsPubmed:29670923
- Changes in the concentrations of inflammatory and oxidative status biomediators (MIP-1 α, PMN elastase, MDA, and IL-12) in depressed patients with and without …Pubmed:29339257
- CQPC06 Activity Prevents Dextran Sulfate Sodium‐Induced Colitis by Regulating the IL‐8 PathwayDoi: 10.1111/1750-3841.14346
- The anti-inflammatory and anti-oxidative effects of conbercept in treatment of macular edema secondary to retinal vein occlusionPubmed: 30558792
- Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stressPubmed: 33227274
- α-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in micePubmed: 32973325
- PIGU promotes hepatocellular carcinoma progression through activating NF-κB pathway and increasing immune escapePubmed: 32971102
- A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapyPubmed: 32332752
- PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L134325342